infusystem.com (INFU) - Long-Term Liabilities to Capital

Corporate emblem and logo of InfuSystem Holdings, Inc. (INFU)

InfuSystem Holdings is expanding partnerships with pump manufacturers and oncology centers to optimize therapy logistics. The company generates revenue through services and the rental of infusion pumps for home treatment, ensuring a steady cash flow. This chart illustrates that the asset's market value is 0.37. High insurance compliance barriers in the US and long-term agreements with clinics strengthen the business's economic moat.

InfuSystem Holdings, Inc. - INFU Long-Term Debt to Capital (period 07/04/2022 - 10/29/2026)

Comprehensive metric breakdowns and analytics for InfuSystem (INFU)

- stock value and consensus price forecast:
Stock Quotes InfuSystem Inc|INFU - Analyst Consensus Forecast
- market capitalization indicators:
Market Value InfuSystem Holdings, Inc.|INFU - Enterprise Value
- book value of equity indicators:
Equity per Share InfuSystem Holdings|INFU - Book Capitalization|Market Capitalization to Book Value infusystem.com|INFU - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio InfuSystem Holdings|INFU - Long-Term Debt to Capital|Short-Term Debt to Capital InfuSystem Inc|INFU - Company Debts|Debt to Book Capitalization Ratio InfuSystem Holdings, Inc.|INFU - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings InfuSystem Holdings|Interim Coverage Ratio infusystem.com
- financial results and valuation multiples details:
INFU - Company Net Income
Comprehensive company analysis:infusystem.com
Signature product of InfuSystem

This ratio determines the proportion of liabilities with a maturity exceeding twelve months within the equity structure, reflecting the degree of financial leverage and the stability of the credit policy. Analyzing the ratio of long-term loans to equity allows for an assessment of the ability of InfuSystem Holdings (INFU) to finance the large-scale deployment of its infusion pump network under strict FDA regulatory oversight.

Competing companies

Long-Term Debt to Equity Ratio Intuitive Surgical, Inc. (ISRG)|Long-Term Debt to Capital DHR|BDX - Long-Term Liabilities to Capital|Long-Term Debt to Capital STE (STERIS plc)|WST: Long-Term Debt to Capital Ratio|Baxter - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Masimo Corp MASI|STVN: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Teleflex Corp|MMSI (Merit Medical Systems) - Long-Term Debt to Capital|Long-Term Debt to Capital envistaco.com|Long-Term Debt to Equity ICU Medical (ICUI)|Long-Term Debt to Equity XRAY (Dentsply Sirona Inc)|LeMaitre - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ATRC|STAAR Surgical Company - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital ChromaDex Corp NAGE|ZimVie (ZIMV) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio ANGO|Long-Term Debt to Equity Cerus Corp|Teknova Inc (TKNO) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio MGRM (Monogram Technologies)|Long-Term Loans to Capital Ratio STSS|Long-Term Debt to Equity Utah Medical Products, Inc. UTMD|Long-Term Debt to Capital Coefficient KRMD|NYXH: Long-Term Debt to Equity Ratio|MBOT - Long-Term Debt to Capital|Pro-Dex, Inc. (PDEX) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio zentek.com|ELUT (Elutia) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Milestone Scientific Inc MLSS|Long-Term Debt to Equity NEXGEL, Inc (NXGL)|retractable.com - Long-Term Debt to Capital Ratio|Harvard Bioscience, Inc. - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio FEMY (femasys.com)|MHUA - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Predictive Oncology POAI|CJMB: Long-Term Debt to Capital|ATRI - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity NeuroMetrix, Inc.